NewTimeSpace News: CK Life Sciences Int'l., (Holdings) Inc. (00775.HK) issued a voluntary announcement on March 10, 2026, announcing the establishment of Sequencio, a wholly-owned subsidiary focused on advancing the development of its portfolio of therapeutic cancer vaccines.

Sequencio consolidates the Group’s therapeutic cancer vaccine R&D programs into a dedicated platform, reflecting the Company’s strategic commitment to expanding in this emerging field of cancer immunotherapy. Sequencio focuses on developing therapeutic vaccines that activate a patient’s own immune system to fight cancer cells, aiming to achieve durable and stable disease remission with a favorable safety profile, addressing key limitations of current standard-of-care therapies. Sequencio has a long-term vision:to redefine the cancer treatment paradigmfrom inducing temporary tumor shrinkage toward long-term controllable remission via the immune system. Vaccine research and design will be conducted by an in-house team, combining internal scientific capabilities and external partnerships to accelerate overall development.

Sequencio’s preclinical pipeline includes the Company’s investigational cancer vaccine targeting Trophoblast Cell-Surface Antigen 2 (TROP2). In preclinical mouse studies of breast cancer and colorectal cancer, this candidate vaccine induced robust T-cell immune responses and achieved100% complete tumor growth inhibition. The pipeline also includes vaccine candidates targeting Preferentially Expressed Antigen in Melanoma (PRAME), Programmed Death-Ligand 1 (PD-L1), the B7-H3 immune checkpoint, and Claudin 6.

With Sequencio, TransCode and Dogwood now under its umbrella, the Company has built a diversified R&D platform covering both early- and late-stage projects, focusing on areas of unmet medical need. Previously, in 2024, the Company completed a transaction with Dogwood Therapeutics, a Nasdaq-listed company, and now holds a majority stake in Dogwood. In 2025, the Company sold seviprotimut-L, a late-stage melanoma vaccine, to TransCode Therapeutics, another Nasdaq-listed company, in exchange for an equity stake.